Hemodynamic sensors for implantable defibrillators  by Mirowski, M. & Mower, Morton M.
656 JACC Vol. 15, No. 3 
March 1. 1990:656-7 
Editorial Comment 
Hemodynamic Sensors for 
Implantable Defibrillators* 
M. MIROWSKI, MD, FACC,t 
MORTON M. MOWER, MD, FACCQ 
Baltimore, Maryland and St. Paul, Minnesota 
During the past decade, the safety, reliability and effective- 
ness of the automatic implantable cardioverter-defibrillator 
(AICD) have been clearly demonstrated in more than 8,000 
patients (1). With these results established, the interest of 
investigators is now being directed toward the development 
and creation of more user-friendly antiarrhythmic electronic 
devices characterized by further structural and functional 
sophistication to minimize false positive responses and to 
provide graded degrees of therapy for the broad spectrum of 
malignant ventricular arrhythmias. Although many areas are 
being explored, particularly pertinent efforts are being ex- 
pended to optimize lead geometry (2,3) and to design more 
accurate diagnostic algorithms. 
Clinical trials are underway that use a transvenous de- 
fibrillating lead paired with a subcutaneous patch to achieve 
efficacious energy distribution of the delivered shock. So far, 
this new system-which has an obvious main advantage of 
obviating the need for thoracotomy-has demonstrated 
promising clinical feasibility (4). 
Hemodynamic sensors for identifying ventricular tachyar- 
rhythmias. Growing attention is being focused on hemody- 
namic sensors to improve ventricular tachyarrhythmia de- 
tection. The use of hemodynamic variables to identify 
ventricular arrhythmias is not new. In fact, the sensing 
subsystem of our first experimental models of the automatic 
implantable defibrillator (AID) was based on monitoring the 
pulsatile right ventricular pressure (5). A sudden drop in this 
pressure indicated the onset of a life-threatening arrhythmia, 
triggering the capacitor charging cycle. The system per- 
formed quite satisfactorily but for reasons of convenience 
was soon replaced by algorithms based on electrical varia- 
bles. There was no doubt in our minds that work in this area 
would be resumed in the future. 
The present study. This prediction is now being fulfilled. 
For example, right ventricular hemodynamics were recently 
studied in animals as a means of distinguishing various types 
of arrhythmias (6); the basic hardware and necessary algo- 
rithms have also been defined for such a hemodynamically 
driven system (7). In the current issue of the Journal, 
Sharma et al. (8) report on the use, in patients, of a catheter 
that incorporates a blood pressure transducer within the lead 
itself. This study is particularly significant because, for the 
first time, a model guided by hemodynamic information is 
being tested in a clinical setting. 
However, the work of Sharma et al. (8) also raises several 
issues. For instance, the authors’ declared goal is to develop 
a system capable of distinguishing hemodynamically stable 
from hemodynamically unstable cardiac arrhythmias, with 
hemodynamic instability defined as loss of consciousness. 
Thus, with their sensing system, only unconscious patients 
would receive defibrillatory shocks, whereas those with 
stable arrhythmias (as defined by Sharma et al.) would be 
treated by pacing and low energy cardioversion. Unfortu- 
nately, the clinical reality is more complex than the scheme 
proposed. Many patients with ventricular fibrillation remain 
conscious for several seconds (9,lO). Should the device, for 
the sake of relative comfort, wait longer than is strictly 
necessary to deliver the life-saving shock? The clear corre- 
lation between the clinical effect of the discharge and the 
time elapsed from the onset of the arrhythmia is well known. 
A more general, but not less important, issue is that the 
AICD is now considered to be the standard of effectiveness 
in the treatment of malignant arrhythmias (I 1,12). Therefore, 
the new, “improved” models of implantable defibrillators 
must demonstrate that they are better than or at least equal 
to the AICD. Because patients with an AICD have a survival 
rate after sudden at-rhythmic death of 98.5% at 1 year and 
95% at 5 years (1,13), any treatment modality that cannot 
demonstrate this degree of effectiveness will have to be 
closely scrutinized. 
References 
1. Clinical Research Department. Report to U.S. Food and Drug Adminis- 
tration. St. Paul, MN: CPI, 1989. 
*Editorials published in Jourtzal of the American College of Cardiology 
reflect the views of the authors and do not necessarily represent the views of 
JACC or the American College of Cardiology. 
From the tDepartments of Medicine, Sinai Hospital of Baltimore and The 
Johns Hopkins Medical Institutions, Baltimore, Maryland and the 
$Department of Medical Sciences, Cardiac Pacemakers, Inc., St. Paul, 
Minnesota. 
Address for reorints: M. Mirowski, MD, Department of Medicine, Sinai 
Hospital of Baltimore, Belvedere at Greenspring, Baltimore, Maryland 21215. 
2. Winkle RA, Bach SM Jr, Mead RH, et al. Comparison of defibrillation 
efficacy in humans using a new catheter and superior vena cava spring-left 
ventricular patch electrodes. J Am Coil Cardiol 1988;11:365-70. 
3. Mirowski M, Mower MM. Transvenous catheter defibrillation for preven- 
tion of sudden cardiac death. J Am Coil Cardiol 1988;11:371-2. 
4. Bach SM Jr, Barstad J, Harper N, et al. Initial clinical experience: 
EndotakTM-implantable transvenous defibrillator system (abstr). J Am 
Coll Cardiol 1989;13(suppl A):65A. 
01990 by the American College of Cardiology 0735-1097/90/$3.50 
JACC Vol. 15. No. 3 MIROWSKI .4ND MOWER 651 
March I, lYYO:656-7 EDITORIAL COMMENT 
5. Mirowski M. Mower MM. Staewen WS. Tabatznik B. Mendeloff Al. 
Standby automattc defibrillator: an approach to prevention of sudden 
coronary death. Arch Intern Med 1970;126:158-61. 
6. Cohen TJ. Veltri EP. Lattuca JJ. Mower MM. Hemodynamic responses 
to rapid pacing: a model for tachycardia differentiation. PACE 198X:1 I: 
122-X. 
7. Cohen TJ. Veltri EP. Mower MM. A hemodynamically responsive 
antitachycardia system: theoretical bases for design. J Electrophys 1988: 
?.7Sl_X, _..._ 
X. Sharma .4D, Bennett TD. Erickson M. et al. Right ventricular pressure 
during ventricular arrhythmias in humans: potential implications for 
implantable antitachycardia devices. J Am Coil Cardiol 1990:15:64X-55. 
9. Tchou PJ. Kadri N. Anderson J. Caceres JA. Jazayeri M. Akhtar M. 
Automattc implantable cardioverter-defibrillators and survival of patients 
with left ventricular dysfunction and malignant ventricular arrhythmias. 
,4nn Intern Med 1988:109:529-34. 
IO. Fogoros RN. Elson JJ. Bonnel CA. Actuarial incidence and pattern of 
occurrence of shocks following implantation of the automatic tmplantable 
cardioverter-defibrillator. PACE 1989:12: 1465-73. 
I I. Fisher JD. Kim SG. Mercando .4D. Electrical devtces for treatment of 
arrhythmias (abstr). Am J Cardiol 1988;61:45A. 
12. Lehmann MH. Steinman RT. Schuger CD. Jackson K. The automatic 
implantable cardioverter defibrillator as antiarrhythmic treatment modal- 
ity of choice for survivors of cardiac arrest unrelated to acute myocardial 
infarction. Am J Cardiol 19XX:62:80!-5. 
13. Winkle RA. Mead RH. Ruder MA. et al. Long-term outcome wtth the 
automatic implantable cardioverter-defibrillator. J :Am Coil Cardiol 1989; 
I?: 1153-61. 
